ArticleLung cancer (Amsterdam, Netherlands)2018
Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
Article in Lung cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Hematological parameters as predictors of immune-related adverse events: risk factor analysis in non-small cell lung cancer patients undergoing immunotherapy.American journal of translational research · 2025Article
- Impact of lymph node involvement in pulmonary carcinoids: a narrative review.Translational lung cancer research · 2024Review
- Validation of IASLC 9th edition TNM classification for lung cancer: focus on N descriptor.BMC cancer · 2024Article
- C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.Scientific reports · 2024Article
- Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer.Journal of translational medicine · 2024Article
- Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe.Immunotherapy · 2024Article
- Functional Status and Survival in Older Nursing Home Residents With Advanced Non-Small-Cell Lung Cancer: A SEER-Medicare Analysis.JCO oncology practice · 2022Article
- Role of Pneumonectomy in T1-4N2M0 Non-Small Cell Lung Cancer: A Propensity Score Matching Analysis.Frontiers in oncology · 2022Article
- hsa_circ_0072309 Expression Profiling in Non-small-Cell Lung Carcinoma and Its Implications for Diagnosis and Prognosis.Frontiers in surgery · 2022Article
- circCD151 promotes GLI2 expression by regulating miR‑30d‑5p and enhancing proliferation, invasion and stemness of lung cancer.Molecular medicine reports · 2021Article
- Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study.World journal of surgical oncology · 2021Article
- Tumor size as a predictor for prognosis of patients with surgical IIIA-N2 non-small cell lung cancer after surgery.Journal of thoracic disease · 2021Article
- Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer.Frontiers in immunology · 2021Article
- Diagnostic and prognostic value of CT perfusion parameters in patients with advanced NSCLC after chemotherapy.American journal of translational research · 2021Article
- miR-130a-Mediated KLF3 Can Inhibit the Growth of Lung Cancer Cells.Cancer management and research · 2021Article
- Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature.Medicine · 2020Review
- A Recurrence-Specific Gene-Based Prognosis Prediction Model for Lung Adenocarcinoma through Machine Learning Algorithm.BioMed research international · 2020Article
- LINC00501 Inhibits the Growth and Metastasis of Lung Cancer by Mediating miR-129-5p/HMGB1.OncoTargets and therapy · 2020Article
- Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients.Scientific reports · 2019Article
- The 8Annals of translational medicine · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byThe 82019
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe compared the performance of 7th and 8th edition of the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) TNM staging for non-small cell lung cancer (NSCLC) in non-metastatic (stage I-III) North American cohort undergoing primary radiation treatment.
methodsNewly diagnosed NSCLC between (Jan 2011 - Dec 2014) were screened through a Canadian Provincial Cancer Registry. Clinico-radiologically and pathologically confirmed non-metastatic NSCLC undergoing primary radiation treatment were included. Kaplan-Meier methods, Cox proportional hazard regression and Akaike information criterion (AIC) were applied to evaluate discriminatory ability and prognostic performance of 7th and 8th edition of staging systems.
resultsIn this cohort of 295 patients, 8th edition stages IA3, IB, IIA, IIB, IIIA, IIIB, and IIIC showed progressive increase in the hazard ratio compared to best stage IA2 (8th edition IA3 vs IA2: HR 1.72; IB vs IA2: HR 2.04; IIA vs IA2: HR 2.66; IIB vs IA2: HR 2.91; IIIA vs IA2: HR 3.38; IIIB vs IA2: HR 3.62 and IIIC vs IA2: HR 8.22). In a multivariate model, 8th edition stage grouping had smaller AIC of 2342.08 compared to 7th edition 2349.55, confirming better performance. International Association for the Study of Lung Cancer (IASLC) map based nodal categorization N1, N2 and N3, showed good survival and hazard discrimination over stage N0 (1.39, 1.48 and 2.16 respectively).
conclusionIn an independent cohort of non-metastatic NSCLC undergoing primary radiation treatment, improved performance of 8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.